1 Introduction Individuals diagnosed with type 2 diabetes mellitus (T2DM) face an increased risk of mortality and cardiovascular problems. SGLT2 inhibitors (SGLT-2i) have received approval to reduce blood glucose levels in adults with T2DM when used in conjunction with diet and exercise. In addition to lowering glucose, SGLT-2i offers additional benefits in addressing various aspects of metabolic syndrome, such as improving blood pressure, weight management, and lipid profiles.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile